Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
In 1994 we saw the 25th anniversary year of the worldwide introduction of anti-rhesus (D) immunoglobulin prophylaxis, one of the most successful prophylactic programmes in medical history. In 1977, 110 cases of stillbirth or neonatal death due to RhD haemolytic disease were registered in Britain; by 1992, this figure seemed to have dropped to nine cases.1 In this issue of the BMJ, however, Whitfield and colleagues show that this is a serious underestimation (p 1504).2 Extrapolation of their Scottish figures suggests that there are 50 deaths a year due to RhD haemolytic disease in Britain. They conclude that the discrepancy is due to underreporting because deaths due to early abortion (before 24 weeks) and late neonatal death (second to fourth week of life) are not included in official figures.
The policy introduced in 1969 was to give anti-D immunoglobulin to RhD negative
women only after the birth of a
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?